SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated as a potential treatment for inflammatory indications identified through the collaboration. As a result of this achievement, Ligand has earned a $500,000 milestone payment from GSK.
